Clinical Trials Logo

Gout clinical trials

View clinical trials related to Gout.

Filter by:

NCT ID: NCT01988402 Completed - Gout Clinical Trials

Does Allopurinol Prolong a Treated, Acute Gout Flare?

Start date: December 2007
Phase: Phase 4
Study type: Interventional

This is a double blind placebo controlled study to determine whether starting allopurinol during a treated acute gout attack will have any effect on the duration of the attack.

NCT ID: NCT01927198 Completed - Gout Clinical Trials

RDEA3170 Monotherapy in Subjects With Gout

Start date: August 2013
Phase: Phase 2
Study type: Interventional

This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.

NCT ID: NCT01884272 Completed - Gout Clinical Trials

NSAID Drug Interaction Study

Start date: June 2013
Phase: Phase 1
Study type: Interventional

This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of non-steroidal anti-inflammatory drugs on lesinurad and leinurad on the non-steroidal anti-inflammatory drugs.

NCT ID: NCT01881919 Completed - Diabetes Clinical Trials

Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial

Start date: February 2013
Phase: Phase 0
Study type: Interventional

The purpose of this study was to test the effect of chronic consumption of Quercetin 500 mg tablets on blood uric acid and other biomarkers in adult males.

NCT ID: NCT01872832 Completed - Gout Clinical Trials

Single and Multiple Dose Study in Japanese Subjects

Start date: June 2013
Phase: Phase 1
Study type: Interventional

This study will explore the safety, tolerability, and serum uric acid lowering effect of RDEA3170 in healthy Japanese males to allow comparison with the Western population.

NCT ID: NCT01830725 Completed - Gout Clinical Trials

Purine Metabolism Enzyme SNP to Uric Acid Production

Start date: December 2012
Phase: N/A
Study type: Observational

Determine whether a relationship exists between polymorphisms of the genes XDH, HPRT1, and PRPS1 and gout, hyperuricemia, or the dose of xanthine oxidase (XO) inhibitors to reach a goal serum uric acid of less than 6 mg/dL. This study is observational in nature as no dose adjustment of XO inhibitors will be made by study investigators.

NCT ID: NCT01818505 Recruiting - Metabolic Syndrome Clinical Trials

The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome

URIC
Start date: March 2013
Phase: N/A
Study type: Observational

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, the investigators will analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. The investigators expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.

NCT ID: NCT01808144 Completed - Gout Clinical Trials

Lesinurad and Febuxostat Combination Extension Study in Gout

Start date: March 1, 2013
Phase: Phase 3
Study type: Interventional

This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with febuxostat over a long-term timeframe.

NCT ID: NCT01808131 Completed - Gout Clinical Trials

Lesinurad and Allopurinol Combination Extension Study in Gout

Start date: February 2013
Phase: Phase 3
Study type: Interventional

This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with allopurinol over a long-term timeframe.

NCT ID: NCT01775098 Withdrawn - Gout Clinical Trials

Allopurinol in Acute Gout

Start date: n/a
Phase: N/A
Study type: Interventional

The objectives of the present study are to determine if starting treatement of hyperuricemia with allopurinol during an acute gout crises has an impact on the duration or the severity of the crises